Open Payments, (more) searchable by anyone

Today we launched openpayments.healthcare, a free platform for exploring the federal Open Payments data by company, drug or device brand, or provider.

Open Payments is the program, created under the Physician Payments Sunshine Act, that requires drug and device companies to report what they pay physicians and teaching hospitals: consulting and speaking fees, research funding, royalties, meals, travel. CMS has published it every year since 2013, and the running total is now north of $70 billion.

The platform is searchable back to 2022, and you can use it to see where a specific provider has a financial relationship, or watch how spending shifts across a whole category as products launch and patents expire.

One note on the data. Open Payments comes in three buckets: General Payments, Research, and Ownership/Investment. This site is focused on General Payments, since that's what most cleanly reads as a commercial tie to a company through a specific product.  

We're also publishing an analysis that pairs drug brand-name payments with prescription claims growth, covering 23 drugs across eight therapeutic categories. A few things that stood out:

• Ozempic's payments rose 246% as Novo Nordisk defended its share of the GLP-1 market against astonishing growth from Eli Lily's Zepbound.
• Humira claims fell 62% as biosimilars arrived. AbbVie's payments tied to Humira total just $725K over three years, comapred $111 million for Skyrizi and $53 million for Rinvoq.
• Leqembi prescriptions climbed from roughly 11,000 in 2023 to about 411,000 in 2025, and its payments jumped the year Lilly's Kisunla launched.
• Comirnaty (COVID-19 vaccine) was the highest-spending product of 2025 at over $538 million, though nearly all of that is a single royalty payment to the Hospital of the University of Pennsylvania.

As new products launch and competitors enter, manufacturers change where and how they invest, and that leaves a public trail of where they're placing their bets.